Altre lingue ImmuPharma plc

Azioni

IMM

GB0033711010

Mercato chiuso - London S.E. Altri mercati azionari 17:35:11 01/07/2024			Variaz. 5gg	Var. 1 gen.
2,17 ^GBX	+4,33%		+0,23%	+30,17%

05/06	ImmuPharma plc riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
29/04	Immunovia annuncia la nomina di Lisa Fordas a Direttore di Laboratorio Clinico	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ImmuPharma : 2024 Result of Annual General Meeting – all resolutions passed	14:16
EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	05/06
ImmuPharma : Annual Report 2023	05/06
ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2023	05/06
ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	05/06
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	29/04
Immupharma jumps amid new IP strategy for P140 technology platform	02/04
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	02/04
ImmuPharma : Incanthera Provides Commercial Update and Revenue Forecasts	26/03
Incanthera says first order from skincare deal doubles	25/03
Stocks make tepid start to new week	25/03
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	25/03
ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments	08/03
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	06/03
TR1 – Major Holding by Lanstead (Date: 28 December 2023)	02/01
ImmuPharma : TR1 – Major holding by Lanstead	20/12
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	19/12
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	19/12
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	19/12
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	19/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ImmuPharma plc

Azioni

IMM

GB0033711010

Altre lingue

Filtri